TN
Tenaya Therapeutics, Inc.
TNYA · NASDAQ
$0.57 -6.28% (-$0.04)
1M -19.10%
Market Cap $122.8M
P/E Ratio -
Div. Yield -
ROE 108.05%
Bulios Fair Price
$0.28
50.5% downside
Current Price
$0.57
Undervalued Fair Value Overvalued
According to Bulios Fair Price, TNYA is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Weak
3/9Valuation
47 /100
Fair P/B 1.77x
P/S 91.95x
P/FFO N/A
Growth
0 /100
Declining Book val. growth 20.29%
Rev. growth N/A
FCF growth N/A
Profitability
20 /100
Weak Net margin 7,723.97%
Op. margin 7,929.89%
FCF margin 5,380.75%
Quality
0 /100
Poor ROE 108.05%
ROA 110.24%
Asset turnover 0.01x
Debt
100 /100
Low Current ratio 4.52x
Debt/Equity 0.06x
Net debt/EBITDA N/A
Stability
42 /100
Moderate EPS volatility 16.47%
Profitable years 0
Beta 2.78x
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about TNYA
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Faraz Ali
Employees
70
Headquarters
South San Francisco
Upcoming events
11 NOV
Earnings
Upcoming earnings report